Bellioni P, Catalano B, Cervellera G, Filiaci F, Mira E, Carraro A
Department of Otorhinolaryngology, Università Cattolica, Sacro Cuore, Rome, Italy.
Rhinology. 1996 Jun;34(2):101-4.
Mizolastine is a new, non-sedating antihistamine providing satisfactory symptomatic relief in seasonal allergic rhinitis. The purpose of this study has been to compare mizolastine to loratadine in perennial allergic rhinitis. This multicentre, double-blind study has involved 68 patients, randomly allocated, after a one-week placebo run-in, to 10 mg mizolastine or 10 mg loratadine, both given on a once-daily basis, for four weeks. Comparable symptom relief occurs in both groups resulting, respectively for mizolastine and loratadine, in a 66.6% and a 61.3% decrease in total nasal score, to a 74.8% and a 76.4% decrease in total ocular score, and to a 69.0% and a 64.8% decrease in global total score. Safety is satisfactory in both groups. Mizolastine is at least as effective as loratadine in relieving perennial allergic rhinitis symptoms and its safety profile allows its use in the treatment of this disease.
咪唑斯汀是一种新型非镇静性抗组胺药，可有效缓解季节性变应性鼻炎的症状。本研究旨在比较咪唑斯汀与氯雷他定治疗常年性变应性鼻炎的疗效。这项多中心、双盲研究共纳入68例患者，在经过为期1周的安慰剂导入期后，将患者随机分为两组，分别给予10 mg咪唑斯汀或10 mg氯雷他定，均每日1次，疗程4周。两组症状缓解程度相当，咪唑斯汀组和氯雷他定组的总鼻症状评分分别降低66.6%和61.3%，总眼症状评分分别降低74.8%和76.4%，整体总评分分别降低69.0%和64.8%。两组安全性均良好。咪唑斯汀在缓解常年性变应性鼻炎症状方面至少与氯雷他定同样有效，且其安全性良好，可用于治疗该病。
